Tier 4 — mechanistic
Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention
Clinical and experimental pharmacology & physiology
2012
39(5):406-411
Bibliography
- PubMed
- PMID 22220931
- Funding
- Funding was not established from the accessible source; this is not a declaration of no funding.
- Competing interests
- A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.
Study snapshot
| Design | Controlled adjunctive clinical biomarker study |
|---|---|
| Model | Human participants; see population |
| Sample | 130 ACS/PCI patients; 61 received adjunctive berberine |
| Intervention | Berberine 300 mg three times/day plus standard care versus standard care |
| Duration | 30 days |
| Endpoints | Cardiac or vascular outcomes; Inflammatory biomarkers; Adverse events |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
